NEW YORK (GenomeWeb) – MDxHealth today reported that its revenues for the first half of 2014 increased 20 percent over the first half of 2013, driven by sales of its ConfirmMDx prostate cancer test.

The Belgian molecular diagnostics firm reported total revenues of $4.8 million for the six months ended June 30, up from $4 million in the first half of 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.